Sarcoma  >>  albumin-bound paclitaxel  >>  Phase 2
Welcome,         Profile    Billing    Logout  

16 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
albumin-bound paclitaxel / Generic mfg.
NCT01055028: Paclitaxel + Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma

Terminated
2
18
US
Bevacizumab, Avastin, Paclitaxel, Abraxane
Stanford University, Genentech, Inc.
Angiosarcomas, Soft Tissue Sarcoma
03/16
06/16
ABRADES, NCT03275818 / 2016-002464-14: Trial of Nab-paclitaxel in Patients With Desmoid Tumors and Multiply Relapsed/Refractory Desmoplastic Small Round Cell Tumors and Ewing Sarcoma

Completed
2
69
Europe
nab paclitaxel, Abraxane
Grupo Espanol de Investigacion en Sarcomas
Tumor, Desmoplastic Small Round Cell, Adult, Tumor, Desmoplastic Small Round Cell, Childhood, Sarcoma, Ewing, Sarcoma, Desmoid
09/21
09/21
NCT04725448: Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma

Recruiting
2
27
RoW
Toripalimab, JS001, Toripalimab Injection, TuoYI, Teruipuli Dankang, Bevacizumab, Bevacizumab Injection, Avastin, Bei Fa Zhu Dankang Zhusheye, Nab-paclitaxel, ABRAXANE, paclitaxel protein-bound particles for injectable suspension, Carboplatin, Carboplatin injection
Sichuan Cancer Hospital and Research Institute
Pulmonary Sarcomatoid Carcinoma, Non-small Cell Lung Cancer, Lung Diseases, Thoracic Neoplasms
03/22
11/23
NCT04859465: Albumin-bound Paclitaxel Combined With Liposomal Doxorubicin in the Treatment of Advanced or Unresectable Angiosarcoma

Recruiting
2
69
RoW
Abraxane combined with liposomal doxorubicin
Sun Yat-sen University
Angiosarcoma Metastatic
05/24
11/24
NCT02945800: Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma

Active, not recruiting
2
59
US
nab-Paclitaxel, Abraxane, Gemcitabine, Gemzar
H. Lee Moffitt Cancer Center and Research Institute, National Pediatric Cancer Foundation
Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Soft Tissue Sarcoma
02/25
02/26
NCT05189483: Albumin-bound Paclitaxel Plus Camrelizumab for Advanced Soft Tissue Sarcoma.

Recruiting
2
40
RoW
Albumin-Bound Paclitaxel, Camrelizumab
Henan Cancer Hospital
Soft Tissue Sarcoma
07/24
07/24
Pan-MSI-ACSE, NCT06333314: Dostarlimab for Locally Advanced or Metastatic Cancer (non-colorectal/non-endometrial) with Tumor DMMR/MSI

Recruiting
2
120
Europe
Dostarlimab, Chemotherapy
UNICANCER, National Cancer Institute, France, GlaxoSmithKline
Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma, Adrenocortical Carcinoma, Neuroendocrine Carcinoma, Soft Tissue Sarcoma, Small Bowel Adenocarcinoma, Duodenum Adenocarcinoma, Gastric Adenocarcinoma
10/28
09/30
Actuate 1801, NCT03678883: 9-ING-41 in Patients With Advanced Cancers

Active, not recruiting
2
350
Europe, Canada, US
9-ING-41, Gemcitabine - 21 day cycle, Gemzar, Doxorubicin., Doxil, Adriamycin, Lomustine, CCNU, Gleostine, Carboplatin., Paraplatin, Nab paclitaxel., Abraxane, Protein-bound paclitaxel, Nanoparticle albumin-bound paclitaxel, Paclitaxel., Taxol, Gemcitabine - 28 day cycle, Irinotecan, Camptosar
Actuate Therapeutics Inc.
Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma
01/25
01/26
ChiCTR2400086577: The efficacy and safety study of adebrelimab in combination with chemotherapy and apatinib for perioperative treatment of lung sarcomatoid carcinoma

Recruiting
2
25
 
Pre-surgical neoadjuvant therapy phase1.Adebrelimab: 1200 mg IV, D1, Q3W, treatment for 2-4 cycles; 2. Apatinib: 250 mg, QD, half hour after meal, treatment for 2-4 cycles; 3. albumin paclitaxel: 260 mg/m2, D1, Q3W; 4. cisplatin: 70 mg/m2, D1, Q3W (no more than 130 mg)/carboplatin: 300-400 mg/m2, D1, Q3W.Chemotherapy may be given in split doses before and after surgery for a total of no more than 4 cycles of treatment.Surgery was performed within 6 weeks of the last neoadjuvant dose, and adjuvant therapy was administered within 6 weeks after surgery as assessed by the investigator.Post-surgical adjuvant therapy phase.Treatment regimen determined by the investigator (Adebrelimab1200 mg + apatinib 250 mg for up to 13 cycles is recommended for driver gene-negative patients; adjuvant treatment with TKIs is selected by the investigator for driver gene-positive patients).
Tianjin Medical University General Hospital; Tianjin Medical University General Hospital, Jiangsu Hengrui Medicine Co.,Ltd.
pulmonary sarcomatoid carcinoma
 
 
NCT03009058 / 2016-001459-28: Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer

Terminated
1/2
2
Europe
IMM-101, Heat killed M. obuense (NCTC) 13365), Gemcitabine, GEMZAR, Nabpaclitaxel, Abraxane, Capecitabine, Folinic Acid, Leucovorin, Fluorouracil, 5FU, Irinotecan, Campto, Camptosar, Oxaliplatin, Eloxatin, cetuximab, Erbitux, Anti-PD1, pembrolizumab (KEYTRUDA),, nivolumab (OPDIVO), Ipilimumab, YERVOY, Cyclophosphamide, cytophosphane
Immodulon Therapeutics Ltd
Metastatic Cancer
08/17
08/17
NCT01962103 / 2013-000144-26: Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors

Completed
1/2
107
Europe, Canada, US
nab-paclitaxel, Abraxane
Celgene
Neuroblastoma, Rhabdomyosarcoma, Ewing's Sarcoma, Ewing's Tumor, Sarcoma, Ewing's, Sarcomas, Epitheliod, Sarcoma, Soft Tissue, Sarcoma, Spindle Cell, Melanoma, Malignant Melanoma, Clinical Oncology, Oncology, Medical, Pediatrics, Osteosarcoma, Osteogenic Sarcoma, Osteosarcoma Tumor, Sarcoma, Osteogenic, Tumors, Cancer, Neoplasia, Neoplasm, Histiocytoma, Fibrosarcoma, Dermatofibrosarcoma
12/17
11/18
PembroPlus, NCT02331251: Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer

Checkmark AACR-NCI-EORTC 2015
Oct 2015 - Oct 2015: AACR-NCI-EORTC 2015
Checkmark IASLC-WCLC 2015
Aug 2015 - Aug 2015: IASLC-WCLC 2015
Terminated
1/2
81
US
Pembrolizumab, Keytruda, Gemcitabine, Gemzar, Docetaxel, Taxotere, Nab-paclitaxel, Abraxane, Vinorelbine, Navelbine, Irinotecan, Camptosar, Liposomal Doxorubicin, Doxil
Western Regional Medical Center
Advanced Cancer, Breast Cancer, Sarcoma, Pancreatic Cancer, Small Cell Lung Cancer, Ovarian
01/18
01/18
NAPAGE, NCT03524898: NAb-PAclitaxel and GEmcitabine in Advanced Soft Tissue Sarcoma

Terminated
1/2
39
Europe
Nab-Paclitaxel, Abraxane, gemcitabine
Swiss Group for Clinical Cancer Research
Soft Tissue Sarcoma
02/22
02/22
NCT04742959: Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

Completed
1/2
203
US
TT-00420, Nab-Paclitaxel
TransThera Sciences (Nanjing), Inc.
Advanced Solid Tumor, Cholangiocarcinoma, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Bladder Cancer, Small-cell Lung Cancer, Prostate Cancer, Thyroid Cancer, Sarcoma, Gastric Cancer, Gallbladder Cancer
02/24
02/24
SC9/ABX, NCT04528680: Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma

Recruiting
1/2
57
US
Sonication for opening of blood-brain barrier, SonoCloud-9 device, SC-9, Chemotherapy, albumin-bound paclitaxel, Abraxane®, ABX, Chemotherapy, carboplatin, Paraplatin
Northwestern University, CarThera, Bristol-Myers Squibb, Lantheus Medical Imaging
Glioblastoma, Gliosarcoma, GBM, Glioblastoma Multiforme, Glioblastoma, IDH-wildtype, Recurrent Glioblastoma
09/24
09/25
NCT05699811: IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors

Recruiting
1/2
40
RoW
MSC-IFNα, Nab paclitaxel, Abraxane, Cyclophosphamide, Anti-PD-1 monoclonal antibody, Toripalimab Injection, Sintilimab Injection, Camrelizumab Injection, Tislelizumab Injection
Chinese PLA General Hospital, Wuxi Sinotide New Drug Discovery Institutes
Locally Advanced or Metastatic Solid Tumors
12/25
12/26

Download Options